STOCK TITAN
  1. Home
  2. News
  3. ATAI

ATAI Life Sciences N.V. Common Shares - ATAI STOCK NEWS

Welcome to our dedicated page for ATAI Life Sciences N.V. Common Shares news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on ATAI Life Sciences N.V. Common Shares stock.

ATAI Life Sciences N.V. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of mental health disorders. Based in the United States and Germany, ATAI leverages a decentralized, technology- and data-driven platform to serve millions suffering from mental health challenges. The company’s mission is to develop innovative treatments that address significant unmet medical needs, leading to paradigm shifts in mental health care.

ATAI's product pipeline includes promising candidates such as COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. These candidates are designed to treat conditions such as depression, anxiety, addiction, and other mental health disorders.

Recently, ATAI announced positive results from its Phase 1 study of EMP-01, the R-enantiomer of MDMA. The study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EMP-01. Involving 32 healthy participants, the study showed that EMP-01 was well-tolerated with no severe adverse events. The PK profile was dose-proportional, and PD measures indicated significant, consistent, and dose-dependent changes. These promising results might pave the way for EMP-01’s further clinical development.

ATAI Life Sciences is committed to efficient drug development by pooling resources, expertise, and best practices across its portfolio. This approach helps mitigate risks and accelerates the development of impactful, evidence-based treatments. The company’s vision is to heal mental health disorders, enabling everyone to live a more fulfilled life.

For more information, visit their official website at www.atai.life.

News

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Rhea-AI Summary
atai Life Sciences dosed the first patient in Part 2 of Beckley Psytech’s Phase 2a study exploring BPL-003 as an adjunctive therapy to SSRIs in patients with Treatment Resistant Depression. Initial results from the monotherapy Part 1 showed positive outcomes, with a rapid and durable antidepressant effect lasting up to 12 weeks post-dose. Part 2 aims to investigate the safety, tolerability, efficacy, and pharmacokinetics of BPL-003 in combination with SSRIs, with results expected in H1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
clinical trial
-
News

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Rhea-AI Summary
atai Life Sciences announced the publication of Beckley Psytech’s Phase 1 study of BPL-003 in the Journal of Psychopharmacology. BPL-003, a novel benzoate salt formulation of 5-MeO-DMT, showed safety, tolerability, and reliable induction of psychedelic effects in healthy participants. The study demonstrated rapid onset and short duration of effects, with potential for scalable single-dose treatment models. Positive participant feedback and plans for Phase 2a and 2b studies in Alcohol Use Disorder and Treatment Resistant Depression highlight the promising future of BPL-003.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags
clinical trial
-
News

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Rhea-AI Summary
Atai Life Sciences (ATAI) announces strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies for mental health disorders. Positive Phase 2a results for BPL-003 in TRD patients show rapid and durable antidepressant effects. Dosing starts for VLS-01 in a Phase 1b study for TRD. Financially, the company expects funding to last into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.06%
Tags
earnings
News

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Rhea-AI Summary
atai Life Sciences (ATAI) announces positive initial results from BPL-003 Phase 2a study in Treatment Resistant Depression (TRD). A single dose demonstrated rapid and durable antidepressant effects, with 45% of patients in remission at week 12. BPL-003 showed good safety profile and was well-tolerated. Phase 2b study in 225 TRD patients underway with top-line results expected in H2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
clinical trial
-
News

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

Rhea-AI Summary
atai Life Sciences initiates Phase 1b trial for VLS-01, a rapid-acting antidepressant for treatment-resistant depression, with promising early results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
clinical trial
-
News

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary
atai Life Sciences to participate in a panel discussion at the TD Cowen conference in Boston, MA on March 4, 2024, aiming to transform mental health treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
conferences
News

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

Rhea-AI Summary
atai Life Sciences (ATAI) announced the appointment of Anne Johnson as Chief Financial Officer, succeeding Stephen Bardin. Johnson brings almost 20 years of biotechnology and pharmaceutical experience and will lead the company's financial organization. The interim CFO, Johnson, has demonstrated executive leadership, financial acumen, and a track record in the biopharmaceutical industry. She will work closely with CEO Florian Brand to execute the company's strategy. Stephen Bardin will continue in an advisory role until March 31, 2024, to support the transition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
management
-
News

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

Rhea-AI Summary
atai Life Sciences (NASDAQ: ATAI) announced a strategic investment in Beckley Psytech Limited to accelerate the development of two patent-protected, clinical-stage psychedelic candidates, BPL-003 and ELE-101. Multiple clinical readouts are anticipated within the next 12 months, including a Phase 2b readout of BPL-003 in Treatment Resistant Depression in 2H24. BPL-003 has the potential to become a first-in-class short-duration psychedelic treatment with rapid acting and durable antidepressant effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.67%
Tags
clinical trial
-
News

atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

Rhea-AI Summary
atai Life Sciences (NASDAQ: ATAI) announced positive results from its Phase 1 study evaluating orally administered EMP-01, the R-enantiomer of MDMA, showing well-tolerated treatment and dose-dependent changes in pharmacokinetics and pharmacodynamics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.86%
Tags
clinical trial
News

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Rhea-AI Summary
atai Life Sciences (NASDAQ: ATAI) reported third quarter 2023 financial results and provided corporate updates. The company's $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. The Phase 2b study of RL-007 in CIAS patients is on track to report data in 2H 2024, and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 demonstrated that 160mg of VLS-01 reached exposure levels comparable to 30mg of IV DMT. The company also announced the acceptance of three non-clinical poster presentations at upcoming medical meetings, including non-clinical data for RL-007 and two novel 5-HT2A receptor agonists, EGX-A and EGX-B.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.13%
Tags
earnings

FAQ

What is the current stock price of ATAI Life Sciences N.V. Common Shares (ATAI)?

The current stock price of ATAI Life Sciences N.V. Common Shares (ATAI) is $1.08 as of November 1, 2024.

What is the market cap of ATAI Life Sciences N.V. Common Shares (ATAI)?

The market cap of ATAI Life Sciences N.V. Common Shares (ATAI) is approximately 182.9M.

What is ATAI Life Sciences N.V.?

ATAI Life Sciences N.V. is a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders using innovative therapeutics.

Where is ATAI Life Sciences based?

ATAI Life Sciences operates in the United States and Germany.

What are some of ATAI Life Sciences' key products?

Key products include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, and EMP-01/MDMA derivative.

What recent achievement has ATAI announced?

ATAI recently announced positive results from its Phase 1 study of EMP-01, showing it to be well-tolerated with significant, consistent, and dose-dependent changes.

What is EMP-01?

EMP-01 is the R-enantiomer of MDMA, currently under clinical investigation for its potential to treat mental health disorders.

What is the mission of ATAI Life Sciences?

ATAI’s mission is to develop innovative treatments for mental health disorders, addressing significant unmet needs and leading to paradigm shifts in mental health care.

How does ATAI Life Sciences accelerate drug development?

ATAI pools resources, expertise, and best practices across its portfolio to mitigate risks and accelerate the development of impactful, evidence-based treatments.

What is the vision of ATAI Life Sciences?

ATAI’s vision is to heal mental health disorders so everyone can live a more fulfilled life.

How can I get more information about ATAI Life Sciences?

You can visit their official website at www.atai.life for more information.

Stock ATAI logo
ATAI Life Sciences N.V. Common Shares

Nasdaq:ATAI

ATAI Rankings

#3928 Ranked by Market Cap
N/A Ranked by Dividends

ATAI Stock Data

182.90M
167.80M
9.99%
27.11%
5.72%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BERLIN